Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57


Mutant calreticulin in myeloproliferative neoplasms.

How J, Hobbs G, Mullally A.

Blood. 2019 Sep 27. pii: blood.2019000622. doi: 10.1182/blood.2019000622. [Epub ahead of print]


The Molecular Genetics of Myeloproliferative Neoplasms.

Marneth AE, Mullally A.

Cold Spring Harb Perspect Med. 2019 Sep 23. pii: a034876. doi: 10.1101/cshperspect.a034876. [Epub ahead of print]


JAK2 (and other genes) be nimble with MPN diagnosis, prognosis, and therapy.

Ciboddo M, Mullally A.

Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):110-117. doi: 10.1182/asheducation-2018.1.110. Review.


The kinases IKBKE and TBK1 regulate MYC-dependent survival pathways through YB-1 in AML and are targets for therapy.

Liu S, Marneth AE, Alexe G, Walker SR, Gandler HI, Ye DQ, Labella K, Mathur R, Toniolo PA, Tillgren M, Gokhale PC, Barbie D, Mullally A, Stegmaier K, Frank DA.

Blood Adv. 2018 Dec 11;2(23):3428-3442. doi: 10.1182/bloodadvances.2018016733.


Gli1+ Mesenchymal Stromal Cells Are a Key Driver of Bone Marrow Fibrosis and an Important Cellular Therapeutic Target.

Schneider RK, Mullally A, Dugourd A, Peisker F, Hoogenboezem R, Van Strien PMH, Bindels EM, Heckl D, Büsche G, Fleck D, Müller-Newen G, Wongboonsin J, Ventura Ferreira M, Puelles VG, Saez-Rodriguez J, Ebert BL, Humphreys BD, Kramann R.

Cell Stem Cell. 2018 Aug 2;23(2):308-309. doi: 10.1016/j.stem.2018.07.006. No abstract available.


Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms.

Wolach O, Sellar RS, Martinod K, Cherpokova D, McConkey M, Chappell RJ, Silver AJ, Adams D, Castellano CA, Schneider RK, Padera RF, DeAngelo DJ, Wadleigh M, Steensma DP, Galinsky I, Stone RM, Genovese G, McCarroll SA, Iliadou B, Hultman C, Neuberg D, Mullally A, Wagner DD, Ebert BL.

Sci Transl Med. 2018 Apr 11;10(436). pii: eaan8292. doi: 10.1126/scitranslmed.aan8292.


Defining the requirements for the pathogenic interaction between mutant calreticulin and MPL in MPN.

Elf S, Abdelfattah NS, Baral AJ, Beeson D, Rivera JF, Ko A, Florescu N, Birrane G, Chen E, Mullally A.

Blood. 2018 Feb 15;131(7):782-786. doi: 10.1182/blood-2017-08-800896. Epub 2017 Dec 29.


JAK2, CALR, MPL and ASXL1 mutational status correlates with distinct histological features in Philadelphia chromosome-negative myeloproliferative neoplasms.

Wong WJ, Hasserjian RP, Pinkus GS, Breyfogle LJ, Mullally A, Pozdnyakova O.

Haematologica. 2018 Feb;103(2):e63-e68. doi: 10.3324/haematol.2017.178988. Epub 2017 Nov 16. No abstract available.


Kinase Inhibitors in the Treatment of Myeloid Malignancies.

Mullally A.

Hematol Oncol Clin North Am. 2017 Aug;31(4):ix-x. doi: 10.1016/j.hoc.2017.05.001. No abstract available.


The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms.

Hobbs GS, Rozelle S, Mullally A.

Hematol Oncol Clin North Am. 2017 Aug;31(4):613-626. doi: 10.1016/j.hoc.2017.04.002. Epub 2017 May 17. Review.


Gli1+ Mesenchymal Stromal Cells Are a Key Driver of Bone Marrow Fibrosis and an Important Cellular Therapeutic Target.

Schneider RK, Mullally A, Dugourd A, Peisker F, Hoogenboezem R, Van Strien PMH, Bindels EM, Heckl D, Büsche G, Fleck D, Müller-Newen G, Wongboonsin J, Ventura Ferreira M, Puelles VG, Saez-Rodriguez J, Ebert BL, Humphreys BD, Kramann R.

Cell Stem Cell. 2017 Jun 1;20(6):785-800.e8. doi: 10.1016/j.stem.2017.03.008. Epub 2017 Apr 27. Erratum in: Cell Stem Cell. 2018 Aug 2;23(2):308-309.


Myeloproliferative neoplasm stem cells.

Mead AJ, Mullally A.

Blood. 2017 Mar 23;129(12):1607-1616. doi: 10.1182/blood-2016-10-696005. Epub 2017 Feb 3. Review.


Gain of function in Jak2V617F-positive T-cells.

Nishanth G, Wolleschak D, Fahldieck C, Fischer T, Mullally A, Perner F, Schnöder TM, Just S, Heidel FH, Schlüter D.

Leukemia. 2017 Apr;31(4):1000-1003. doi: 10.1038/leu.2017.6. Epub 2017 Jan 11. No abstract available.


Physiologic Expression of Sf3b1(K700E) Causes Impaired Erythropoiesis, Aberrant Splicing, and Sensitivity to Therapeutic Spliceosome Modulation.

Obeng EA, Chappell RJ, Seiler M, Chen MC, Campagna DR, Schmidt PJ, Schneider RK, Lord AM, Wang L, Gambe RG, McConkey ME, Ali AM, Raza A, Yu L, Buonamici S, Smith PG, Mullally A, Wu CJ, Fleming MD, Ebert BL.

Cancer Cell. 2016 Sep 12;30(3):404-417. doi: 10.1016/j.ccell.2016.08.006.


Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation.

Elf S, Abdelfattah NS, Chen E, Perales-Patón J, Rosen EA, Ko A, Peisker F, Florescu N, Giannini S, Wolach O, Morgan EA, Tothova Z, Losman JA, Schneider RK, Al-Shahrour F, Mullally A.

Cancer Discov. 2016 Apr;6(4):368-81. doi: 10.1158/2159-8290.CD-15-1434. Epub 2016 Mar 7.


RECQL5 Suppresses Oncogenic JAK2-Induced Replication Stress and Genomic Instability.

Chen E, Ahn JS, Sykes DB, Breyfogle LJ, Godfrey AL, Nangalia J, Ko A, DeAngelo DJ, Green AR, Mullally A.

Cell Rep. 2015 Dec 22;13(11):2345-2352. doi: 10.1016/j.celrep.2015.11.037. Epub 2015 Dec 10.


Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition.

Wen QJ, Yang Q, Goldenson B, Malinge S, Lasho T, Schneider RK, Breyfogle LJ, Schultz R, Gilles L, Koppikar P, Abdel-Wahab O, Pardanani A, Stein B, Gurbuxani S, Mullally A, Levine RL, Tefferi A, Crispino JD.

Nat Med. 2015 Dec;21(12):1473-80. doi: 10.1038/nm.3995. Epub 2015 Nov 16.


Haemophagocytic lymphohistiocytosis in adults: a multicentre case series over 7 years.

Schram AM, Comstock P, Campo M, Gorovets D, Mullally A, Bodio K, Arnason J, Berliner N.

Br J Haematol. 2016 Feb;172(3):412-9. doi: 10.1111/bjh.13837. Epub 2015 Nov 5.


How does JAK2V617F contribute to the pathogenesis of myeloproliferative neoplasms?

Chen E, Mullally A.

Hematology Am Soc Hematol Educ Program. 2014 Dec 5;2014(1):268-76. doi: 10.1182/asheducation-2014.1.268. Epub 2014 Nov 18. Review.


Marked hyperferritinemia does not predict for HLH in the adult population.

Schram AM, Campigotto F, Mullally A, Fogerty A, Massarotti E, Neuberg D, Berliner N.

Blood. 2015 Mar 5;125(10):1548-52. doi: 10.1182/blood-2014-10-602607. Epub 2015 Jan 8.


Role of the clathrin adaptor PICALM in normal hematopoiesis and polycythemia vera pathophysiology.

Ishikawa Y, Maeda M, Pasham M, Aguet F, Tacheva-Grigorova SK, Masuda T, Yi H, Lee SU, Xu J, Teruya-Feldstein J, Ericsson M, Mullally A, Heuser J, Kirchhausen T, Maeda T.

Haematologica. 2015 Apr;100(4):439-51. doi: 10.3324/haematol.2014.119537. Epub 2014 Dec 31.


Dynamin 2-dependent endocytosis is required for normal megakaryocyte development in mice.

Bender M, Giannini S, Grozovsky R, Jönsson T, Christensen H, Pluthero FG, Ko A, Mullally A, Kahr WH, Hoffmeister KM, Falet H.

Blood. 2015 Feb 5;125(6):1014-24. doi: 10.1182/blood-2014-07-587857. Epub 2014 Dec 2.


Hit the spleen, JAK!

Lane SW, Mullally A.

Blood. 2014 Nov 6;124(19):2898-900. doi: 10.1182/blood-2014-09-600635.


JAK2V617F promotes replication fork stalling with disease-restricted impairment of the intra-S checkpoint response.

Chen E, Ahn JS, Massie CE, Clynes D, Godfrey AL, Li J, Park HJ, Nangalia J, Silber Y, Mullally A, Gibbons RJ, Green AR.

Proc Natl Acad Sci U S A. 2014 Oct 21;111(42):15190-5. doi: 10.1073/pnas.1401873111. Epub 2014 Oct 6.


Distinct effects of concomitant Jak2V617F expression and Tet2 loss in mice promote disease progression in myeloproliferative neoplasms.

Chen E, Schneider RK, Breyfogle LJ, Rosen EA, Poveromo L, Elf S, Ko A, Brumme K, Levine R, Ebert BL, Mullally A.

Blood. 2015 Jan 8;125(2):327-35. doi: 10.1182/blood-2014-04-567024. Epub 2014 Oct 3.


Role of casein kinase 1A1 in the biology and targeted therapy of del(5q) MDS.

Schneider RK, Ademà V, Heckl D, Järås M, Mallo M, Lord AM, Chu LP, McConkey ME, Kramann R, Mullally A, Bejar R, Solé F, Ebert BL.

Cancer Cell. 2014 Oct 13;26(4):509-20. doi: 10.1016/j.ccr.2014.08.001. Epub 2014 Sep 18.


Loss of function of TET2 cooperates with constitutively active KIT in murine and human models of mastocytosis.

De Vita S, Schneider RK, Garcia M, Wood J, Gavillet M, Ebert BL, Gerbaulet A, Roers A, Levine RL, Mullally A, Williams DA.

PLoS One. 2014 May 2;9(5):e96209. doi: 10.1371/journal.pone.0096209. eCollection 2014.


Csnk1a1 inhibition has p53-dependent therapeutic efficacy in acute myeloid leukemia.

Järås M, Miller PG, Chu LP, Puram RV, Fink EC, Schneider RK, Al-Shahrour F, Peña P, Breyfogle LJ, Hartwell KA, McConkey ME, Cowley GS, Root DE, Kharas MG, Mullally A, Ebert BL.

J Exp Med. 2014 Apr 7;211(4):605-12. doi: 10.1084/jem.20131033. Epub 2014 Mar 10.


A prospective cohort study of alcohol exposure in early and late pregnancy within an urban population in Ireland.

Murphy DJ, Dunney C, Mullally A, Adnan N, Fahey T, Barry J.

Int J Environ Res Public Health. 2014 Feb 17;11(2):2049-63. doi: 10.3390/ijerph110202049.


Sinister symbiosis: pathological hematopoietic-stromal interactions in CML.

Mullally A, Ebert BL.

Cell Stem Cell. 2013 Sep 5;13(3):257-8. doi: 10.1016/j.stem.2013.08.009.


Population-based study of smoking behaviour throughout pregnancy and adverse perinatal outcomes.

Murphy DJ, Dunney C, Mullally A, Adnan N, Deane R.

Int J Environ Res Public Health. 2013 Aug 27;10(9):3855-67. doi: 10.3390/ijerph10093855.


Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-α in a murine model of polycythemia vera.

Mullally A, Bruedigam C, Poveromo L, Heidel FH, Purdon A, Vu T, Austin R, Heckl D, Breyfogle LJ, Kuhn CP, Kalaitzidis D, Armstrong SA, Williams DA, Hill GR, Ebert BL, Lane SW.

Blood. 2013 May 2;121(18):3692-702. doi: 10.1182/blood-2012-05-432989. Epub 2013 Mar 13.


Behavioural change in relation to alcohol exposure in early pregnancy and impact on perinatal outcomes--a prospective cohort study.

Murphy DJ, Mullally A, Cleary BJ, Fahey T, Barry J.

BMC Pregnancy Childbirth. 2013 Jan 16;13:8. doi: 10.1186/1471-2393-13-8.


Myeloproliferative neoplasm animal models.

Mullally A, Lane SW, Brumme K, Ebert BL.

Hematol Oncol Clin North Am. 2012 Oct;26(5):1065-81. doi: 10.1016/j.hoc.2012.07.007. Epub 2012 Aug 21. Review.


Janus reveals another face: the biologic rationale for targeting Janus kinase 2 in lymphoma.

Mullally A, Ebert BL.

J Clin Oncol. 2012 Nov 20;30(33):4168-70. doi: 10.1200/JCO.2012.44.0347. Epub 2012 Sep 10. No abstract available.


miR-433 is aberrantly expressed in myeloproliferative neoplasms and suppresses hematopoietic cell growth and differentiation.

Lin X, Rice KL, Buzzai M, Hexner E, Costa FF, Kilpivaara O, Mullally A, Soares MB, Ebert BL, Levine R, Licht JD.

Leukemia. 2013 Feb;27(2):344-52. doi: 10.1038/leu.2012.224. Epub 2012 Aug 6.


Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy.

Koppikar P, Bhagwat N, Kilpivaara O, Manshouri T, Adli M, Hricik T, Liu F, Saunders LM, Mullally A, Abdel-Wahab O, Leung L, Weinstein A, Marubayashi S, Goel A, Gönen M, Estrov Z, Ebert BL, Chiosis G, Nimer SD, Bernstein BE, Verstovsek S, Levine RL.

Nature. 2012 Sep 6;489(7414):155-9. doi: 10.1038/nature11303.


Distinct roles for long-term hematopoietic stem cells and erythroid precursor cells in a murine model of Jak2V617F-mediated polycythemia vera.

Mullally A, Poveromo L, Schneider RK, Al-Shahrour F, Lane SW, Ebert BL.

Blood. 2012 Jul 5;120(1):166-72. doi: 10.1182/blood-2012-01-402396. Epub 2012 May 24.


EXEL-8232, a small-molecule JAK2 inhibitor, effectively treats thrombocytosis and extramedullary hematopoiesis in a murine model of myeloproliferative neoplasm induced by MPLW515L.

Wernig G, Kharas MG, Mullally A, Leeman DS, Okabe R, George T, Clary DO, Gilliland DG.

Leukemia. 2012 Apr;26(4):720-7. doi: 10.1038/leu.2011.261. Epub 2011 Oct 18.


Coordinate loss of a microRNA and protein-coding gene cooperate in the pathogenesis of 5q- syndrome.

Kumar MS, Narla A, Nonami A, Mullally A, Dimitrova N, Ball B, McAuley JR, Poveromo L, Kutok JL, Galili N, Raza A, Attar E, Gilliland DG, Jacks T, Ebert BL.

Blood. 2011 Oct 27;118(17):4666-73. doi: 10.1182/blood-2010-12-324715. Epub 2011 Aug 26.


Prevalence, predictors and perinatal outcomes of peri-conceptional alcohol exposure--retrospective cohort study in an urban obstetric population in Ireland.

Mullally A, Cleary BJ, Barry J, Fahey TP, Murphy DJ.

BMC Pregnancy Childbirth. 2011 Apr 11;11:27. doi: 10.1186/1471-2393-11-27.


Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH Symposium.

Tefferi A, Abdel-Wahab O, Cervantes F, Crispino JD, Finazzi G, Girodon F, Gisslinger H, Gotlib J, Kiladjian JJ, Levine RL, Licht JD, Mullally A, Odenike O, Pardanani A, Silver RT, Solary E, Mughal T.

Blood Cancer J. 2011 Mar 4;1:e7. doi: 10.1038/bcj.2011.4.


STATistical power of clonal analysis: differential STAT1 pathway activation downstream of the JAK2V617F mutation.

Mullally A, Ebert BL.

Cancer Cell. 2010 Nov 16;18(5):405-6. doi: 10.1016/j.ccr.2010.10.037. No abstract available.


Haploinsufficiency for ribosomal protein genes causes selective activation of p53 in human erythroid progenitor cells.

Dutt S, Narla A, Lin K, Mullally A, Abayasekara N, Megerdichian C, Wilson FH, Currie T, Khanna-Gupta A, Berliner N, Kutok JL, Ebert BL.

Blood. 2011 Mar 3;117(9):2567-76. doi: 10.1182/blood-2010-07-295238. Epub 2010 Nov 10.


NF1 inactivation revs up Ras in adult acute myelogenous leukemia.

Mullally A, Ebert BL.

Clin Cancer Res. 2010 Aug 15;16(16):4074-6. doi: 10.1158/1078-0432.CCR-10-1438. Epub 2010 Jun 29. Review.


Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells.

Mullally A, Lane SW, Ball B, Megerdichian C, Okabe R, Al-Shahrour F, Paktinat M, Haydu JE, Housman E, Lord AM, Wernig G, Kharas MG, Mercher T, Kutok JL, Gilliland DG, Ebert BL.

Cancer Cell. 2010 Jun 15;17(6):584-96. doi: 10.1016/j.ccr.2010.05.015.


CNS relapse in acute promyeloctyic leukemia.

Housman E, Chang P, Lane SW, Blinder R, Galinsky I, Kesari S, Ho VT, Stone RM, Mullally A.

J Clin Oncol. 2010 Aug 20;28(24):e409-11. doi: 10.1200/JCO.2009.27.1577. Epub 2010 Jun 7. No abstract available.


Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies.

Abdel-Wahab O, Mullally A, Hedvat C, Garcia-Manero G, Patel J, Wadleigh M, Malinge S, Yao J, Kilpivaara O, Bhat R, Huberman K, Thomas S, Dolgalev I, Heguy A, Paietta E, Le Beau MM, Beran M, Tallman MS, Ebert BL, Kantarjian HM, Stone RM, Gilliland DG, Crispino JD, Levine RL.

Blood. 2009 Jul 2;114(1):144-7. doi: 10.1182/blood-2009-03-210039. Epub 2009 May 6.

Supplemental Content

Loading ...
Support Center